Interim analysis results of a phase 1b, multiple ascending dose study to evaluate DX-2930, a fully human monoclonal antibody inhibitor of plasma kallikrein in development for long-term prophylaxis of hereditary angioedema
ALLERGY(2015)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要